Colony-stimulating factors detected in tumor cells and voided urine are potential prognostic markers for patients with muscle-invasive bladder cancer undergoing radical cystectomy

References

• RajGVKaravadiaSSchlomerBContemporary use of perioperative cisplatin-based chemotherapy in patients with muscle-invasive bladder cancerCancer2011117227628220830767
   PubMed Web of Science ®Google Scholar
• FroehnerMKochRHeberlingUDecreased overall and bladder cancer-specific mortality with adjuvant chemotherapy after radical cystectomy: multivariable competing risk analysisEur Urol201569698498726194042
   PubMed Web of Science ®Google Scholar
• SternbergCNde MulderPHSchornagelJHRandomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumorsJ Clin Oncol200119102638264611352955
   PubMed Web of Science ®Google Scholar
• HeaneyMLToyELVekemanFComparison of hospitalization risk and associated costs among patients receiving sargramostim, filgrastim, and pegfilgrastim for chemotherapy-induced neutropeniaCancer2009115204839484819637341
   PubMed Web of Science ®Google Scholar
• HidakaTAkadaSTeranishiAMirimostim (macrophage colony-stimulating factor; M-CSF improves chemotherapy-induced impaired natural killer cell activity, Th1/Th2 balance, and granulocyte functionCancer Sci200394981482012967481
   PubMed Web of Science ®Google Scholar
• OhnoRMiyawakiSHatakeKHuman urinary macrophage colony-stimulating factor reduces the incidence and duration of febrile neutropenia and shortens the period required to finish three courses of intensive consolidation therapy in acute myeloid leukemia: a double-blind controlled studyJ Clin Oncol1997158295429659256140
   PubMed Web of Science ®Google Scholar
• MehtaHMMalandraMCoreySJG-CSF and GM-CSF in neutropeniaJ Immunol201519541341134926254266
   PubMed Web of Science ®Google Scholar
• BehnesCLBremmerFHemmerleinBStraussAStrobelPRadzunHJTumor-associated macrophages are involved in tumor progression in papillary renal cell carcinomaVirchows Arch2014464219119624327306
   PubMed Web of Science ®Google Scholar
• KacinskiBMScataKACarterDFMS (CSF-1 receptor) and CSF-1 transcripts and protein are expressed by human breast carcinomas in vivo and in vitroOncogene1991669419521829808
   PubMed Web of Science ®Google Scholar
• RamakrishnanSXuFJBrandtSJNiedelJEBastRCJrBrownELConstitutive production ofmacrophage colony-stimulating factor by human ovarian and breast cancer cell linesJ Clin Invest19898339219262646321
   PubMed Web of Science ®Google Scholar
• HirasawaKKitamuraTOkaTMatsushitaHBladder tumor producing granulocyte colony-stimulating factor and parathyroid hormone related proteinJ Urol20021675213011956459
   PubMed Web of Science ®Google Scholar
• NebikerCAHanJEppenberger-CastoriSGM-CSF production by tumor cells is associated with improved survival in colorectal cancerClin Cancer Res201420123094310624737547
   PubMed Web of Science ®Google Scholar
• KangMKimHSJeongCWKwakCKimHHKuJHPrognostic factors for conditional survival in patients with muscle-invasive urothelial carcinoma of the bladder treated with radical cystectomySci Rep201551217126212449
   PubMed Web of Science ®Google Scholar
• HinataNMiyakeHMiyazakiANishikawaMTeiHFujisawaMPerformance status as a significant prognostic predictor in patients with urothelial carcinoma of the bladder who underwent radical cystectomyInt J Urol201522874274625988857
   PubMed Web of Science ®Google Scholar
• TürkölmezKTokgözHReşorluBKöseKBedükYMuscle-invasive bladder cancer: predictive factors and prognostic difference between primary and progressive tumorsUrology200770347748117905100
   PubMed Web of Science ®Google Scholar
• SejimaTMorizaneSYaoAPrognostic impact of preoperative hematological disorders and a risk stratification model in bladder cancer patients treated with radical cystectomyInt J Urol201421525723711293
   PubMed Web of Science ®Google Scholar
• NakagawaTHaraTKawaharaTPrognostic risk stratification of patients with urothelial carcinoma of the bladder with recurrence after radical cystectomyJ Urol20131891275128123123368
   PubMed Web of Science ®Google Scholar
• MorizawaYMiyakeMShimadaKExtended resection including adjacent organs and Ki-67 labeling index are prognostic factors in patients with retroperitoneal soft tissue sarcomasWorld J Surg Oncol20161414326911364
   PubMed Web of Science ®Google Scholar
• YeiSBartholomewRMPezzoliPNovel membrane-bound GM-CSF vaccines for the treatment of cancer: generation and evaluation of mbGM-CSF mouse B16F10 melanoma cell vaccineGene Ther20029191302131112224013
   PubMed Web of Science ®Google Scholar
• ZhangXShiXLiJA novel therapeutic vaccine of mouse GM-CSF surface modified MB49 cells against metastatic bladder cancerJ Urol201218731071107922266013
   PubMed Web of Science ®Google Scholar
• MorizawaYMiyakeMShimadaKNeutrophil-to-lymphocyte ratio as a detection marker of tumor recurrence in patients with muscle-invasive bladder cancer after radical cystectomyUrol Oncol20163461117
   Web of Science ®Google Scholar
• WilcoxRACancer-associated myeloproliferation: old association, new therapeutic targetMayo Clin Proc201085765666320592171
   PubMed Web of Science ®Google Scholar
• MizutaniYOkadaYTerachiTKakehiYYoshidaOSerum granulocyte colony-stimulating factor levels in patients with urinary bladder tumor and various urological malignanciesBr J Urol19957655805868535676
   PubMedGoogle Scholar
• TachibanaMMiyakawaATazakiHAutocrine growth of transitional cell carcinoma of the bladder induced by granulocyte-colony stimulating factor-1Cancer Res19955515343834437542171
   PubMed Web of Science ®Google Scholar
• HongISStimulatory versus suppressive effects of GM-CSF on tumor progression in multiple cancer typesExp Mol Med2016487e24227364892
   PubMed Web of Science ®Google Scholar
• KumariNAgrawalUMishraAKPredictive role of serum and urinary cytokines in invasion and recurrence of bladder cancerTumour Biol2017394114
   Google Scholar
• BarnesGPathakASchwartzbergLG-CSF utilization rate and prescribing patterns in United States: associations between physician and patient factors and GCSF useCancer Med2014361477148425410813
   PubMed Web of Science ®Google Scholar
• KudererNMDaleDCCrawfordJLymanGHImpact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic reviewJ Clin Oncol200725213158316717634496
   PubMed Web of Science ®Google Scholar
• PerezFAFlignerCLYuEYRapid clinical deterioration and leukemoid reaction after treatment of urothelial carcinoma of the bladder: possible effect of granulocyte colony-stimulating factorJ Clin Oncol20092734215217
   Web of Science ®Google Scholar
• ShameemIAKurisuHMatsuyamaHShimabukuroTNaitoKDirect and indirect effects of recombinant human granulocyte-colony stimulating factor on in vitro colony formation of human bladder cancer cellsCancer Immunol Immunother19943863533577515769
   PubMed Web of Science ®Google Scholar
• WanLZhangYLaiYEffect of granulocyte-macrophage colony-stimulating factor on prevention and treatment of invasive fungal disease in recipients of allogeneic stem-cell transplantation: a prospective multi-center randomized phase IV trialJ Clin Oncol201533343999400626392095
   PubMed Web of Science ®Google Scholar